[DOI] [PMC free article] [PubMed] [Google Scholar] 26.Togi S., Kamitani S., Kawakami S., Ikeda O., Muromoto R., Nanbo A., Matsuda T
Over the last decade, pharmaceutical manufacturers have been producing improved versions of GLP-1 drugs to treat diabetes, obesity and most recently cardiovascular disease, marketed as Ozempic and Wegovy, among others
This article is part of the PlexusDx Education Hub evidence-based guidance on GLP-1 therapies, telehealth credentialing, and the genetic variables behind every metabolic decision
Visceral Fat Reduction Visceral fat nestles deep in the abdomen, hugging organs
Slow titration and microdosing Some Zealthy providers recommend a slower titration schedule for patients sensitive to gastrointestinal side effects